Skip to main content
HCPCS J0738 · Level II · Part B drug

J0738: lenacapavir, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0738

Billing unit
1 MG
Hiv prep, inj, lenacapavir
ASP payment limit
$16.016
October 2026; -0.4% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0880
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J0738 is the Level II code for Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv), billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $16.016 per billing unit, down 0.4% from July 2026. Under OPPS it carries status indicator K in APC 0880. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names lenacapavir: J1961 (for HIV treatment only; Sunlenca from Gilead Sciences, Inc); J0752 (oral route; billed per 300 mg). No current Billing and Coding Article lists J0738, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0738 at $16.016 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $16.081 in July 2026. Beneficiary coinsurance is 0%.

ASP payment limits for J0738
QuarterPayment limitPerCoinsurance
October 2026$16.0161 MG0%
July 2026$16.0811 MG—
CMS note: HIV PrEP drug

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk lists no NDC for J0738. Report the NDC from the product label and confirm the units conversion from the HCPCS descriptor (Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)).

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J0738 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for J0738 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0738 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0738 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0738 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J0738 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0738 carries status indicator K and is assigned to APC 0880, with a published national unadjusted payment of $16.016. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0738 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $16.02 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J0738 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0738

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0738

What does HCPCS code J0738 describe?

J0738 is defined by CMS as "Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0738 a CPT code?

No. J0738 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as lenacapavir; CPT codes are five-character codes maintained by the AMA. On a Part B claim J0738 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0738 in October 2026?

The ASP-based payment limit is $16.016 per 1 MG, with 0% beneficiary coinsurance. The July 2026 limit was $16.081. Commercial payers use their own fee schedules.

Does J0738 have NCCI bundling edits?

No active practitioner PTP pairs list J0738 as a column-1 or column-2 code in the v323r0 release.

J0738 vs J1961: what is the difference?

Both are HCPCS Level II codes whose descriptor names lenacapavir. What sets J1961 apart: for HIV treatment only; Sunlenca from Gilead Sciences, Inc. J0738 is billed per 1 mg, limit $16.016; J1961 is billed per 1 mg, limit $22.937. Report the code whose descriptor matches the product and setting in the record.

J0738 vs J0752: what is the difference?

Both are HCPCS Level II codes whose descriptor names lenacapavir. What sets J0752 apart: oral route; billed per 300 mg. J0738 is billed per 1 mg, limit $16.016; J0752 is billed per 300 mg, limit $617.946. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.